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Abstract: 
The metabolites of tebufenozide, a model compound, formed by the yeast-expressed human 
CYP3A4 and CYP2C19 were identified to clarify the substrate recognition mechanism of the 
human cytochrome P450 (CYP) isozymes.  We then determined whether tebufenozide metabolites 
may be predicted in silico.  Hydrogen abstraction energies were calculated with the density 
functional theory method B3LYP/6-31G*.  A docking simulation was performed using FRED 
software.  Several alkyl sites of tebufenozide were hydroxylated by CYP3A4 whereas only one 
site was modified by CYP2C19.  The accessibility of each site of tebufenozide to the reaction 
center of CYP enzymes and the susceptibility of each hydrogen atom for metabolism by CYP 
enzymes were evaluated by a docking simulation and hydrogen abstraction energy estimation, 
respectively.  
 
Keywords: CYP3A4; CYP2C19; tebufenozide metabolites; docking simulation; hydrogen 





Humans are exposed on a daily basis to many chemicals and agrochemicals as residues in food 
and water or through occupational use.  Metabolism and efflux systems have been developed to 
detoxify the xenobiotics absorbed by the body. The major metabolic pathways are mediated by the 
cytochrome P450 (CYP) superfamily, and genetic polymorphisms have been identified among the 
CYP isozymes. Therefore, examining the metabolic reactions by each CYP isozyme is important to 
elucidate their substrate recognition mechanisms. The clarification of these mechanisms may be 
useful not only for risk assessments of chemicals for humans, but also the development of new 
drugs and agrochemicals.  
In the present study, we identified the 
metabolites of the insecticide, tebufenozide, 
(Figure 1) formed by two human CYP isozymes: 
CYP3A4 and CYP2C19. CYP3A4 accounts for 
almost 50% of all CYP proteins in the human 
liver, and is the CYP isozyme involved in the 
metabolism of approximately 60% of 
commercially available drugs.
1
 Therefore, it is 
recognized as an isozyme that metabolizes substrates with diverse structures.
 1
 CYP2C19 accounts 
for less than 1% of all CYP proteins, but it is known for genetic polymorphisms, for which 
approximately 20% of the Japanese population express the poor metabolizer phenotype.
2
  The 
substrate recognition mechanism of CYP2C19 needs to be elucidated in more detail because low 
CYP2C19 activity may lead to metabolic problems.  Tebufenozide is an insect growth regulator 
that binds to ecdysone receptors,
3
 and is, thus, a safe insecticide for humans.  However it has the 
asymmetrical hydrazine structure attached to two benzene rings with different substituents. Due to 
its unique asymmetrical structure, it was selected as a model compound for metabolism in this study.  
It is useful for elucidation of the substrate recognition mechanism to know how three different alkyl 
substituents, ethyl, dimethyl, t-butyl groups of tebufenozide are metabolized by different CYPs. 
Since one metabolite of tebufenozide, in which the ethyl-CH2 group of the B-ring is hydroxylated, 
is a chiral compound, we synthesized one enantiomer of the metabolite and determined the R : S 
ratio of the metabolite by each CYP isozyme.   
It was then determined whether the in silico prediction of the metabolites of tebufenozide was 
possible.  We used the combined model of a docking simulation and hydrogen abstraction energy 
estimation for the metabolites of tebufenozide by CYP3A4 and CYP2C19.  If there are several 
sites with sufficient accessibility in a compound, more susceptible sites will be metabolized, leading 
Structure of tebufenozide 
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to the metabolite being hydroxylated at the site.  CYP enzymes metabolize substrates in multiple 
steps, including hydrogen atom abstraction from a substrate by an activated oxygen intermediate in 
the enzyme active site.
4,5
  Since the rate-determining step for the hydroxylation reaction was 
attempted to be hydrogen atom abstraction, the abstraction energy of each hydrogen atom of a 
substrate may predict the susceptibility of metabolism by CYP enzymes.
 4,5
  Olsen et al. reported a 
strong correlation between hydrogen abstraction energy and bond dissociation energy in 
transition-state models containing an activated oxygen intermediate and various substrates.
4
  Thus, 
the bond dissociation energy was calculated for the different types of hydrogen atoms of 
tebufenozide as a substitute for the hydrogen abstraction energy.  A docking simulation was 
carried out to evaluate the accessibility of each hydrogen atom of tebufenozide to the reaction site 
of CYP3A4 and CYP2C19.   
   
2. Results 
 
2.1. Identification of metabolites 
Tebufenozide was metabolized to three compounds M1, M3, and M4 (numbered according to the 
order of the HPLC retention time), by the recombinant yeast cells expressing human CYP3A4 and 
three compounds M1, M2, and M5 by CYP2C19.  These metabolites were isolated and their 
structures, except for the M2 metabolite, were identified by their spectral data.  The mass spectral 
data of M1, M3, and M4 indicated that they had the mono-hydroxylated tebufenozide structures.  
In comparison with the 
1
H NMR spectrum of tebufenozide, the 4-ethyl-CH2 and -CH3 hydrogen 
atoms on the B-ring were shifted from  2.63 (2H) and 1.20 to 4.89 (1H) and 1.45 ppm, 
respectively, in M1.  Furthermore, the broad peak of an OH hydrogen was appeared at 1.85 ppm 
in M1.  Thus, M1 was found to have a structure in which the 1-position of the ethyl group on the 
B-ring was hydroxylated.  Since M1 has an asymmetric carbon atom at the hydroxylated site and, 
thus, it is a chiral compound, we synthesized racemic compound (±)-1 and the R-enantiomer (R-1) 
of M1 in order to determine the R : S ratio of the metabolite by individual CYP isozymes.  The R : 
S ratios of the metabolite by CYP3A4 and CYP2C19 were 33 : 67 and 2 : 98, respectively.  In a 
similar manner, based on the chemical shift changes in the hydrogen atoms, one methyl group on 
the A-ring and of the t-butyl group were hydroxylated in M3 and M4, respectively. 
The MS data and 
1
H NMR spectrum of M5 showed the existence of a CH=CH2 structure 
(molecular weight: 350,  5.33, 5.86 and 6.73 ppm) instead of the ethyl group on the B-ring, 
suggesting the dehydration of M1 or dehydrogenation of tebufenozide catalyzed by CYP.
6
   
Conversion of the ethyl group of tebufenozide to an acetyl group was suggested in M2, based on 
the MS data (molecular weight: 366) and 
1
H NMR spectrum [ 2.59 ppm (3H, s)] of M2.  
 5 
However, it was difficult to elucidate the M2 structure due to the keto-enol tautomeric property of 
the compound.  In some of the molecules, the acetyl group on the B-ring was considered to be 
converted to the enol form in the presence of acetic acid, which was used under the final HPLC 
purification condition.  Thus, a compound with the putative M2 structure was synthesized.  The 
HPLC and NMR data of the synthetic compound which was purified by recrystallization were 
consistent with the keto form of M2.  Thus, the M2 structure was determined as 
N-(4-acetylbenzoyl)-N’-(3,5-dimethylbenzoyl)-N’-t-butylhydrazine (2).   
The proposed MS fragmentation pathways for tebufenozide metabolites were shown in Figure 2, 
supporting the above metabolite structure identification. 
The structures of the metabolites M1-M5 were shown with the production ratio of metabolites in 
Figure 3.  The ethyl-CH2 group of the B-ring (M1), one methyl group of the A-ring (M3), and the 
t-butyl group (M4) were hydroxylated in metabolites by CYP3A4.  In contrast, only the ethyl-CH2 
group of the B-ring was modified in three metabolites by CYP2C19.  These results showed that 
the substrate-binding site of CYP3A4 was larger than that of CYP2C19.  Thus, substrates may 
interact with CYP3A4 by various binding modes, but by limited modes with CYP2C19.  
The enzyme kinetics of M1 were investigated.  Km and Vmax were 6.8 M and 12.7 
mol/min/mol P450 for CYP3A4 and 1.7 M and 2.1 mol/min/mol P450 for CYP2C19.  The 
affinity of tebufenozide for CYP2C19 was 4-fold higher than that for CYP3A4 whereas the 
maximum rate by CYP2C19 was 6-fold lower than that by CYP3A4. 
 
 




Fig. 3.  Structures of tebufenozide metabolites with the production ratio by CYP3A4 and 
CYP2C19 
 
2.2. In silico prediction of metabolites 
The bond dissociation energy, E, was calculated for the different types of hydrogen atoms of 
tebufenozide as a substitute for the hydrogen abstraction energy, as listed in Table 1.  A smaller 
E value reflected the higher metabolism susceptibility of the group.  Susceptibility was higher in 
the order of the ethyl-CH2 of the B-ring, NH, methyl of the A-ring, ethyl-CH3 of the B-ring, t-butyl 
groups, and phenyl-H atoms. 
 
Table 1.  Bond dissociation energies of 
different types of hydrogen atoms of 
tebufenozide 
Type of hydrogen  E(kcal/mol) 
a
 
A-ring Me 87 
B-ring Ethyl-CH2 82 





 The zero-point vibrational energy was 
added. 
 
A docking simulation was carried out to evaluate the accessibility of each hydrogen atom of 
tebufenozide to the reaction site of CYP3A4 and CYP2C19.  Many crystal structures are available 




), which are the 
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complex with a ligand and have better resolutions (2 Å and 2.15 Å, respectively), were used for 
docking.  The crystal structure (PDBID: 4GQS, chain A
9
) was used for human CYP2C19.  The 
100 poses obtained after the constraint filtering for each CYP enzyme were visualized by VIDA, 
version 4.2.1 (OpenEye Scientific Software, Inc.; Santa Fe, New Mexico, USA).  In these poses, 
the closest hydrogen atom to the oxygen atom attached to the heme-iron atom was considered to be 
abstracted and oxidized.  The oxidation (hydroxylation) sites, frequency% and the rank number of 
the highest ranked pose with the score (absolute value) for each site were shown in Table 2.  
 8 
 
Table 2. Oxidation sites, their frequency%, and the rank number of the highest ranked pose 
 (absolute value of score) of 100 poses by the docking simulation for each site  
Oxidation Site CYP3A4   CYP2C19 
 
3UA1   3NXU 
 
    













A-ring Methyl 36 3 (12.88) 
 
16 3 (11.23) 
 
0 - 




26 1 (12.79) 




74 4 (12.23) 
t-Butyl 42 1 (13.13) 
 





 2 62 (11.76)  23 7 (10.72)  0 - 
a
 Absolute value of the Chemgauss4 score.  The larger value, the better docking pose.  
 
b





The oxidation site of the top pose for both structures of CYP3A4 (3UA1 and 3NXU) was the 
t-butyl group.  The poses in which the t-butyl group was oxidized also appeared with the highest 
frequency.  The second site was the methyl group of the A-ring.  There were no poses in which 
the ethyl group of the B-ring was oxidized when the 3NXU structure was used for docking, whereas 
17 and 3 poses in which the oxidation sites were the ethyl-CH2 and -CH3 group of the B-ring, 
respectively, were found using the 3UA1 structure.  The NH group did not appear to be oxidized in 
the top 100 poses for both CYP3A4 structures.  We also attempted to use the chain B of the 3NXU 
crystal structure, which has two chains A and B, for docking, and it was found that the result was 
similar to that using the chain A even if several residue positions are different in each chain (data 
not shown).  In a comparison of the docking results, the docking using 3UA1, having a smaller 
volume of the active site shape predicted the oxidized sites of tebufenozide better than that using 
3NXU; however, it was difficult to predict the ratio of the experimentally obtained metabolites. 
Furthermore, the docking using 3UA1 gave the better score, for example, 13.13 and 11.54 for the 
best poses at the t-butyl group for 3UA1 and 3NXU, respectively.  
Regarding CYP2C19, the only poses in which the ethyl group of the B-ring (CH2 or CH3) was 
oxidized were found at the frequency ratio (CH2 : CH3) = 26 : 74.  We also used the chain C of 
4GQS for docking because the chains A and C of 4 chains of the 4GQS crystal structure have no 
missing portions.  Although only 13 poses were obtained after the constraint filtering due to the 
smaller volume of the active site shapes than that of the chain A (388 Å
3
 vs. 400 Å
3
), the ethyl 
group of the B-ring in all poses except one pose (B-ring 3-H) was the closest moiety to the heme.  
The examples of the docking poses in which the ethyl-CH2 were closest to the heme are shown in 
Figure 4.   
 
Fig. 4.  Examples of docking poses of tebufenozide to CYP3A4 (PDB ID: 3UA1) (A) and 
CYP2C19 (B).  Active site shapes and tebufenozide are shown by blue lines and the 





3.1. Metabolites of tebufenozide 
Metabolites of tebufenozide have been detected in rats.
10
 M1 (RH1788), M2 (RH6595), and M3 
(RH9886) have been identified as rat metabolites and are also common in animals, plants and the 
environment.  M5 (RH9841) has been found in crops.
11
  To date, only M4 in which the t-butyl 
group was hydroxylated has not been reported as a tebufenozide metabolite.  We carried out a 
metabolic reaction of tebufenozide using human liver microsomes (HLM) and rat liver microsomes 
(RLM) and analyzed the metabolites by HPLC and LC/MS (data not shown).  The metabolites, 
M1-M5 were detected in both reaction solutions after 1 hr.  M4 and M5 were minor metabolites in 
humans and rats, and thus they have not been reported as animal metabolites.  However, the 
production ratios of M1-M5 by HLM and RLM were almost identical, showing the similarity of 
both metabolism systems as already known.  
 
3.2. In silico prediction of metabolites 
The in silico prediction of metabolism by CYP enzymes has been performed from the point of 
view of toxicology and drug design.
12
  Prediction methodologies have been classified into four 
categories: [1] substrate orientation-based predictions, [2] mechanism-based predictions, [3] 
empirical and knowledge-based predictions such as quantitative structure-activity relationship 
models and rule-based expert systems, and [4] combined models of [1]-[3].
12
  For category [1], the 
spatial alignment of substrates for the active site of CYP enzymes is important for the metabolic 







predict energetically favorable binding conformations of the ligand into the active site cavity.    
Mechanism-based prediction approaches (category [2]) focus on the rate-limiting step of the 
catalytic cycle by estimating the activation energies of hydrogen abstraction.  Activation energies 




 as well 
as the density functional theory (DFT) method in previous studies including the pioneering work of 
Korzekwa et al.
4,5,18,19
   
As an example of the category [3], Sheridan et al. reported empirical regioselectivity models for 
a few CYP enzymes.
20
  They estimated the AM1 dehydrogenation energy with a quantitative 
structure-activity relationship model using descriptors related to the local chemical environment of 
the atoms such as topological substructure parameters and hydrophobic moments.  One of the 
combined methods, the category [4], was reported by Rydberg et al., named as SMARTCyp.
21
  
SMARTCyp uses a reactivity descriptor and an accessibility descriptor for the 2D structure of 
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drug-like molecules.  The reactivity descriptor is an estimation of the energy required for a CYP to 
react with this position, which is similar to the approach by Singh et al.
5
  The energy was 
calculated for fragments and matching of the fragments was performed for the 2D structure of a 
molecule.  The accessibility descriptor is similar to that defined by Sheridan et al.
20
 as described 
above.   The combined approach of ligand-based pharmacophore modeling with structure-based 
protein modeling by Groot et al.
22
 and the combined model of catalyticphore-based docking with 
activation energy estimation, MLite
23
 have also been reported.  Recent versions of MetaSite
24
 
which uses both simplified docking by molecular interaction fields and fragment-based reactivity 
evaluation is classified into the category [4].  We took the combined model of a docking 
simulation for the accessibility and hydrogen abstraction energy estimation for susceptibility to 
predict the metabolites of tebufenozide by CYP3A4 and CYP2C19.  
Regarding docking into CYP2C19, the only poses in which the ethyl group of the B-ring (CH2 
or CH3) was oxidized were found in the top 100 poses by the Chemgauss4 score.  Since the space 
around the heme Fe=O in CYP2C19 is narrow, only the ethyl group was allowed and fit in the space.  
The 3,5-dimethylbenzene and t-butyl group are bulky and, thus, they may not be allowed in the 
binding cavity.  Three metabolites, in which only the ethyl-CH2 group of the B-ring was modified, 
were experimentally obtained by the reaction with CYP2C19.  Since the bond dissociation energy 
of ethyl-CH3 was higher than that of ethyl-CH2 (17 kcal/mol difference in Table 1), the oxidation 
sites were successfully predicted in silico.  
Docking poses, in which the t-butyl, methyl of the A-ring, ethyl group of the B-ring (CH2 or 
CH3), and others (the 4-H on the A-ring and the 3-H of the B-ring) were oxidized, were found for 
CYP3A4 using the 3UA1 protein structure.  The t-butyl, methyl of the A-ring, and the ethyl-CH2 
group of the B-ring were experimentally oxidized by CYP3A4.  Phenyl hydrogen atoms were not 
considered to be oxidized based on the highest bond dissociation energy of the hydrogen atoms on 
the benzene rings.  Although the ethyl-CH3 group may be metabolized by the docking simulation, 
the frequency for the site was lower (only 3 poses) than those of the other sites.  In addition, the 
high hydrogen dissociation energy and high flexibility of ethyl-CH3 made the metabolic reaction at 
the site unfavorable.  Docking using 3UA1 with a smaller volume of the active site shape 
predicted the oxidized sites of tebufenozide better than that using 3NXU as described previously.  
CYP3A4 metabolizes various compounds.  The binding of larger ligands such as ketoconazole, 
ritonavir, and erythromycin has been shown to require significant conformational changes in 
CYP3A4, while the binding of smaller ligands, even progesterone, induced no or very little 
conformational changes in the protein.
25
  Since tebufenozide does not appear to be a large ligand, 
docking using 3UA1 may give a better result.    
Although the oxidation sites were predicted by docking simulation using the 3UA1 protein 
 12 
structure, the production ratio of metabolites in Figure 3 was not explained by the frequency of the 
poses.  However, the order of the susceptibility by the bond dissociation energy corresponded with 
the production ratio.   
It was difficult to predict the R : S ratios of M1 by CYP3A4 and CYP2C19 in silico; however, 
the greater production of the S-enantiomer was predicted by a docking simulation (R : S = 6 : 11 for 
CYP3A4 (3UA1), 9 : 17 for CYP2C19).  It may be difficult to detect such a subtle difference in 
the substrate orientation by the present docking algorithm.   
 
4. Conclusions 
Human CYP3A4 and CYP2C19 metabolized tebufenozide to five compounds (M1-M5) 
hydroxylated at different positions.  Regarding the in silico prediction of metabolites, the 
accessibility of each site of tebufenozide to the reaction center of CYP enzymes and the 
susceptibility of each hydrogen atom for metabolism by CYP enzymes were evaluated by a docking 
simulation and hydrogen abstraction energy estimation, respectively.  The hydroxylated sites and 
the production order of the metabolism of tebufenozide by CYP2C19 were successfully predicted 
by the combination of these two procedures.  In the case of the metabolism by CYP3A4, the 
combination of the dissociation energies and the docking against 3UA1 could reasonably explain 
the hydroxylated sites and the production order.  Even if there is only one example using a model 
compound, the combined models which were used in this study are expected to be useful for 
metabolite prediction.  This in silico prediction of metabolites will provide important insights in 
order to elucidate the substrate recognition mechanisms of CYPs.  The development of the models 
is now in progress for various compounds. 
 
5. Material and methods 
5.1. Chemicals 
The standard of tebufenozide and -nicotinamide adenine dinucleotide phosphate reduced 
tetrasodium salt (NADPH) were purchased from Wako Pure Chemical Industries (Osaka, Japan) 
and Sigma-Aldrich Co. LLC (St. Louis, Missouri, USA), respectively.  All other reagents were of 
analytical grade and purchased from Wako Pure Chemical Industries or Nacalai Tesque (Kyoto, 
Japan).  Microsomes containing baculovirus-expressed human CYP3A4 or CYP2C19 were 
purchased from Japan Corning Inc. (Tokyo, Japan).   
Recombinant S. cerevisiae AH22 cells expressing human CYP3A4 or CYP2C19 with the 
vector pGYR were used to produce the metabolites of tebufenozide (4).
26
 The vector pGYR is an 
episomal S. cerevisiae/E. coli shuttle vector that contains S. cerevisiae NADPH-P450 reductase 






5.2. Metabolism of tebufenozide by CYPs 
The reaction mixture contained 200 M tebufenozide with 1% of acetonitrile and microsomes 
containing 67 nM human CYP3A4 or CYP2C19 in 100 mM phosphate buffer, pH 7.4.  After a 2 
min preincubation at 37
o
C, the reaction was initiated by the addition of NADPH at a final 
concentration of 1 mM at 37
o
C (in total 300 l).  The reaction was terminated by the addition of 
600 l of acetonitrile and vigorous shaking after various time intervals.  After centrifugation of the 
reaction solution (7,000 G, 10 min), the acetonitrile phase was analyzed by HPLC (Shimadzu 
LC-10) and LC/MS (Shimadzu LCMS-2020).   
HPLC analysis conditions; column: TSKgel ODS-100V 3m (4.6 x 150 mm), temperature: 40°C, 
solvent: A: 0.1% acetic acid in water; B: 0.1% acetic acid in methanol, gradient: B: 65% (0 
min)-65% (5 min)-80% (20 min)-100% (21 min)-100% (24 min), flow rate: 0.7 ml/min, detection: 
UV 240 nm 
 
LC/MS analysis condition; LC; column: TSKgel ODS-100V 3m (2.0 x 150 mm), temperature: 
40°C, solvent: A: 0.1% acetic acid in water; B: 0.1% acetic acid in acetonitrile, gradient: B: 42% (0 
min)-42% (5 min)-63% (25 min)-90% (27 min)-90% (29 min), flow rate: 0.2 ml/min, detection: UV 
240 nm; MS; ion source: ESI, polarity: positive ion mode, monitor ions: 100-500 m/z 
 
5.3. Isolation and identification of metabolites 
Recombinant yeast cells expressing human CYP3A4 or expressing CYP2C19 were cultivated in 
a synthetic minimal medium containing 8% glucose, 5.4% yeast nitrogen base with ammonium 
sulfate, and 160 g/ml L-histidine.  Tebufenozide in acetonitrile was added at a final concentration 
of 20 M (2% acetonitrile) to the yeast cell culture.  The yeast cell culture was cultivated at 30oC 
for 24 hrs.  After centrifugation of the yeast cell culture (6,000 G, 3 min), the supernatant was 
partitioned with ethyl acetate.  The organic layer was dried over anhydrous sodium sulfate, and 
concentrated in vacuo.  The residual oil dissolved in a small amount of methanol was purified by 
silica gel (Wakogel C-200, 7 g) column chromatography with a stepwise gradient of n-hexane-ethyl 
acetate.  The fractions eluted with 50% ethyl acetate in n-hexane were further purified by ODS 
column chromatography （YMC ODS-AM 120-S50, 14.8 g） with a stepwise gradient of 0.1% 
acetic acid in water-0.1% acetic acid in methanol.  The fraction eluted with 0.1% acetic acid in 
60% methanol was concentrated, and injected into an HPLC column.  The compounds eluted at 
the retention time (tR) 9.5 min and 12 min in the following HPLC condition were collected to give 
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metabolites M1 and M2, respectively.  The fraction eluted with 0.1% acetic acid in 70% methanol 
was concentrated, and injected into an HPLC column.  The compounds eluted at tR 10.5 min, 14.5 
min, and 15 min in the HPLC conditions described below were collected to give metabolites M3, 
M4, and M5, respectively.  M1 (2.4 mg), M3 (0.2 mg) and M4 (0.1 mg) were obtained from a 1.2 
L yeast cell culture expressing CYP3A4, while M1 (5.9 mg), M2 (0.2 mg), and M5 (3.1 mg) were 
obtained from a 1.35 L yeast cell culture expressing CYP2C19.  
1
H-NMR spectra were measured 
with a Bruker Avance III 400 (400 MHz for 
1
H) instrument.  Mass spectra were measured with a 
JEOL JMS-600H mass spectrometer, Shimadzu LCMS-2020, and/or Thermo Fisher Scientific 
EXACTIVE.  UV spectra were recorded with a Shimadzu UV-2200AI spectrometer. 
HPLC isolation conditions; column: YMC ODS-AQ AQ-311 (6.0 x 100 mm), temperature: 40°, 
solvent: M1 and M2: 0.1% acetic acid in 60% methanol; M3, M4 and M5: 0.1% acetic acid in 70% 
methanol, flow rate: 1.0 ml/min, detection: UV 240 nm 
 
Tebufenozide (measured for comparison, only spectrum is available in ref. 27) 
1
H NMR (CDCl3): 7.56 (1H, s, NH), 7.33 and 7.30 (each 2H, d, each J = 8 Hz, C6H4 of the 
B-ring), 7.05 (2H, s, 2,6-H of the A-ring), 6.92 (1H, s, 4-H of the A-ring), 2.63(2H, q, J = 8 Hz, 
Et-CH2), 2.22 (6H, s, 2CH3 on the A-ring), 1.59 (9H, s, C(CH3)3), 1.20(3H, t, J = 8 Hz, Et-CH3) 
 
M1 (compound 1) 
1
H NMR (CDCl3): 7.66 (1H, s, NH), 7.33 and 7.30 (each 2H, d, each J = 8 Hz, C6H4 of the 
B-ring), 7.05 (2H, s, 2,6-H of the A-ring), 6.92 (1H, s, 4-H of the A-ring), 4.89 (1H, q, J = 8 Hz, 
Et-CH), 2.23 (6H, s, 2CH3 on the A-ring), 1.85 (1H, br, OH), 1.59 (9H, s, C(CH3)3), 1.45 (3H, d, J 
= 8 Hz, Et-CH3).  MS EI m/z (rel. int.): 105 (11), 133 (100), 149 (23), 218 (1), 312 (26), 368 [M]
+
 
(1).   HRMS EI m/z [M]
+
: Calcd. for C22H28N2O3: 368.2100, Found: 368.2066 
 
M2 (compound 2) 
1
HNMR (CDCl3): 7.89 and 7.37 (each 2H, d, each J = 8 Hz, C6H4 of the B-ring), 7.62 (1H, s, 
NH), 7.00 (2H, s, 2,6-H of the A-ring), 6.94 (1H, s, 4-H of the A-ring), 2.59 (3H, s, COCH3), 2.24 
(6H, s, 2CH3 on the A-ring), 1.60 (9H, s, C(CH3)3).  MS EI m/z (rel. int.): 105 (34), 133 (100), 146 
(9), 389 [M+Na]
+
 (9), 405 [M+K]
+
 (10)  
 
M3 (compound 3) 
1
HNMR (400 MHz, CDCl3): 7.67 (1H, s, NH), 7.29 and 7.15 (each 2H, d, each J = 8 Hz, C6H4 of 
the B-ring), 7.10 (1H, s, 4-H of the A-ring), 4.59 (2H, d, J = 4 Hz, CH2OH), 2.63 (2H, q, J = 8 Hz, 
Et-CH2), 7.15 (2H, s, 2,6-H of the A-ring), 2.28 (3H, s, CH3 on the A-ring), 1.59 (9H, s, C(CH3)3), 
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1.20 (3H, t, J = 8 Hz, Et-CH3).  MS EI m/z (rel. int.): 105 (4), 121 (3), 133 (70), 149 (100), 312 
(39), 368 [M]
+
 (1).  HRMS EI m/z [M]
+
: Calcd. for C22H28N2O3: 368.2100, Found: 368.2100 
 
M4 (compound 4) 
1
HNMR (CD3OD): 7.33 and 7.21 (each 2H, d, each J = 8 Hz, C6H4 of the B-ring), 7.07 (2H, s, 
2,6-H of the A-ring), 6.99 (1H, s, 4-H of the A-ring), 4.08 (1H, d, J = 12 Hz, CH2OH), 3.83 (1H, d, 
J = 12 Hz, CH2OH), 2.65 (2H, q, J = 8 Hz, Et-CH2), 2.25 (6H, s, 2CH3 on the A-ring), 1.52 and 
1.48 (each 3H, s, C(CH3)2 of t-butyl), 1.20 (3H, t, J = 8 Hz, Et-CH3).  MS EI m/z (rel. int.): 105 
(12), 133 (79), 205 (100), 337 (7), 368 [M]
+
 (7).  HRMS EI m/z [M]
+
: Calcd. for C22H28N2O3: 
368.2100, Found: 368.2005 
 
M5 (compound 5) 
1
HNMR (CD3OD): 7.43 and 7.36 (each 2H, d, each J = 7 Hz, C6H4 of the B-ring), 7.07 (2H, s, 
2,6-H of the A-ring), 6.99 (1H, s, 4-H of the A-ring), 6.73 (1H, q, J = 18 Hz，11 Hz, CH=CH2), 5.86 
(1H, d, J = 18 Hz, CH=CH2), 5.33 (1H, d, J = 11 Hz, CH=CH2), 2.25 (6H, s, 2CH3 on the A-ring), 
1.59 (9H, s, C(CH3)3).  MS EI m/z (rel. int.): 105 (19), 131 (29), 133 (100), 149 (24), 294 (28), 350 
[M]
+
 (2).  HRMS EI m/z [M]
+
: Calcd. for C22H26N2O2: 350.1994, Found: 350.1960 
 
5.4. Synthesis of compounds (±)-1, R-1 and 2 
The synthesis scheme of the compounds (±)-1, R-1 and 2 is shown in Figure 5.  Compound 2 
was reduced to (±)-1 by NaBH4 and to the R-1 by (S)-(-)-2-methyl-CBS-oxazaborolidine.  
 
Fig. 5. The synthesis scheme of compounds with the M1 structure (racemic compound and 
R-enantiomer) and M2 structure 
 
5.4.1. Preparation of N-(4-acetylbenzoyl)-N’-t-butylhydrazine (7) 
4-Acetylbenzoyl chloride (6) (6.1 mmol) in 10 ml ether and 6 N NaOH (2 ml) were 
simultaneously added dropwise to t-butylhydrazine hydrochloride (6.7 mmol) solution in 10 ml 
ether.  After stirring the mixture for 3 hrs at room temperature, 100 ml of saturated NaCl was 
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added and the reaction product was extracted with ether (50 ml x 3 times).  The ether layer was 
dried over anhydrous sodium sulfate.  The solvent was removed under reduced pressure to give 
crude N-(4-acetylbenzoyl)-N’-t-butylhydrazine (7) (yield 74%).  It was used to the next reaction 
without purification.    
5.4.2. Preparation of N-(4-acetylbenzoyl)-N’-(3,5-dimethylbenzoyl)-N’-t-butylhydrazine (2) 
Pyridine (1.49 mmol) was added to crude N-(4-acetylbenzoyl)-N’-t-butylhydrazine (7) (1.49 
mmol) solution in 1.5 ml ether.  3,5-Dimethylbenzoyl chloride (8) (1.49 mmol) in 1.5 ml ether was 
added dropwise to the reaction mixture.  After the mixture was stirred for 3 hrs at room 
temperature, it was purified by silica gel (Wakogel C-300, 20 g) column chromatography in a 
stepwise manner using mixed solvents: hexane/chloroform, hexane/ethyl acetate, and 
chloroform/methanol.  The fraction eluted with chloroform : methanol = 6 : 1 was further purified 
by silica gel (Wakogel C-300, 6 g) column chromatography with chloroform : ethyl acetate = 10 : 1.  
The fraction eluted with 48 ml of the solvent was concentrated, and the residue was recrystallized 
from a chloroform-hexane mixture to give colorless crystals (58 mg, yield 11%).  
1
H NMR 
(CDCl3):  7.90 and 7.36 (each 2H, d, each J = 8 Hz, C6H4 of the B-ring), 7.62 (1H, s, NH), 7.00 
(2H, s, 2,6-H of the A-ring), 6.94 (1H, s, 4-H of the A-ring), 2.59 (3H, s, COCH3), 2.24 (6H, s, 
2CH3 on the A-ring), 1.60 (9H, s, C(CH3)3).  MS ESI m/z (rel. int.): 105 (33), 133 (100), 146 (3), 
389 [M+Na]
+
 (7), 405 [M+K]
+
 (9).  HRMS ESI m/z [M+H]
+
: Calcd. for C22H29N2O3: 367.2016, 
Found: 367.2008 
 
5.4.3. Preparation of racemic N-(4-(1-hydroxyethyl)benzoyl)-N’-(3,5-dimethylbenzoyl)- 
N’-t-butylhydrazine [(±)-1] 
Sodium borohydride (274 nmol) was added to 
N-(4-acetylbenzoyl)-N’-(3,5-dimethylbenzoyl)-N’-t-butylhydrazine (2) (137 nmol) solution in 5 ml 
methanol.  After stirring the mixture for 25 min at -10
o
C, 10 ml saturated NaHCO3 aq. solution 
and 20 ml dichloromethane were added to the reaction mixture which was then stirred for 5 min at 
0
o
C.  The dichloromethane layer was dried over anhydrous sodium sulfate.  After the filtrated 
dichloromethane layer was concentrated, the residue was purified by silica gel (Wakogel C-300, 1.5 
g) column chromatography with chloroform : ethyl acetate = 5 : 1 (12.3 mg, yield 24%).  
1
H NMR 
(CDCl3):  7.99 (1H, s, NH), 7.27 and 7.26 (each 2H, d, each J = 7 Hz, C6H4 of the B-ring), 7.01 
(2H, s, 2,6-H of the A-ring), 6.91 (1H, s, 4-H of the A-ring), 4.86 (1H, q, J = 7 Hz, Et-CH), 2.21 
(6H, s, 2CH3 on the A-ring), 2.15 (1H, br, OH), 1.57 (9H, s, C(CH3)3), 1.43 (3H, d, J = 7 Hz, 
Et-CH3).  MS ESI m/z (rel. int.): 313 (72), 369 [M+1]
+
 (100).  HRMS ESI m/z [M+H]
+
: Calcd. 
for C22H29N2O3: 369.2173, Found: 369.2166 
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5.4.4. Preparation of (R)-N-(4-(1-hydroxyethyl)benzoyl)-N’-(3,5-dimethylbenzoyl)- 
N’-t-butylhydrazine (R-1) 
(S)-(-)-2-Methyl-CBS-oxazaborolidine ((S)-CBS, 27 nmol) and borane dimethyl sulfide complex 
in 2 M toluene (0.27 mmol) were added to 
N-(4-acetylbenzoyl)-N’-(3,5-dimethylbenzoyl)-N’-t-butylhydrazine (2) (270 nmol) solution in 5 ml 
tetrahydrofuran.  After the mixture was stirred for 3 hr at room temperature, 5 ml methanol was 
added at 0
o
C.  The mixture was further stirred for 30 min at room temperature.  After the solvent 
of the reaction mixture was evaporated, the residue was purified by silica gel (Wakogel C-300, 5 g) 
column chromatography with chloroform : ethyl acetate = 4 : 1 and then 3 : 1 (85 mg, yield 85%).  
1
H NMR (CDCl3):  7.71 (1H, s, NH), 7.32 and 7.29 (each 2H, d, each J = 8 Hz, C6H4 of the 
B-ring), 7.04 (2H, s, 2,6-H of the A-ring), 6.92 (1H, s, 4-H of the A-ring), 4.89 (1H, q, J = 7 Hz, 
Et-CH), 2.23 (6H, s, 2CH3 on the A-ring), 1.89 (1H, br, OH), 1.59 (9H, s, C(CH3)3), 1.45 (3H, d, J 
= 7 Hz, Et-CH3).  MS ESI m/z (rel. int.): 313 (81), 369 [M+1]
+
 (100).  HRMS ESI m/z [M+H]
+
: 
Calcd. for C22H29N2O3: 369.2173, Found: 369.2167.  []D17 = +15.4°(c 5.4, MeOH) 
 
5.4.5. Determination of the R : S ratio of the M1 metabolite by each CYP 
The R : S ratio of the M1 metabolites by each CYP was determined based on the HPLC retention 
time of the synthesized reference compounds.  R-1 and (±)-1 were analyzed by HPLC using a 
chiral column.  The R : S ratio of the racemic compound was 1 : 1 as expected whereas that of 
R-enantiomer was 95 : 5, showing efficient chiral synthesis.   
HPLC analysis condition; Column: CHIRALPAK AZ-H 3M (4.6 x 250 mm); Temperature: 25°C, 
Solvent: 90%hexane/7% 2-propanol/3% methanol, flow rate: 0.5 ml/min; UV detection: 240 nm 
 
5.4.6. Enzyme kinetics for M1 production 
The reaction mixture contained 1-50 M tebufenozide with 2% of acetonitrile and the 
microsomes containing 67 nM human CYP3A4 or CYP2C19 in 100 mM phosphate buffer, pH 7.4.  
After a 2 min preincubation at 37
o
C, the reaction was initiated by the addition of NADPH at a final 
concentration of 1 mM at 37
o
C (in total 300 l).  After 5 min and 10 min for the reaction by 
CYP3A4 and CYP2C19, respectively, the reaction was terminated by the addition of 600 l of 
acetonitrile and vigorous shaking.  After centrifugation of the reaction solution (7,000 G, 10 min), 
the acetonitrile phase was analyzed by HPLC and the amount of M1 was calculated at each 
tebufenozide concentration.  Based on the relationship between tebufenozide concentration and 
reaction rate (mol/min/mol P450), Km and Vmax were calculated using Prism ver. 5.01 (Graphpad 




6.1. Calculation of hydrogen abstraction energies 
The X-ray crystallographic structure of a derivative of tebufenozide (the compound having no 
substituents on benzene rings)
28
 was modified to construct the structure of tebufenozide.  The 
constructed structure of tebufenozide was energy-minimized by Tripos force fields using Sybyl ver. 
7.3 (Sybyl Molecular Modeling Software; Tripos Associates, Inc.; St. Louis, Missouri, USA). The 
radical structures of tebufenozide were constructed by removing one hydrogen atom each from the 
energy-minimized tebufenozide structure. The energies of the radical and initial structures of 
tebufenozide, and a hydrogen atom were calculated with DFT method B3LYP (unrestricted 
formalism for open-shell systems)
29-31
 using Spartan version 10 (Wavefunction, Inc.; Irvine, 
California, USA).  The 6-31G* basis set was used in the B3LYP calculations (unrestricted 
formalism for open-shell systems).  To save the computational time, the bond dissociation energy, 
E, which is the difference in energy between the substrate and the sum of the radical of the 
substrate and hydrogen atom, using optimized geometries for all three species, was simply 
calculated for each hydrogen atom as a substitute for the hydrogen abstraction energy by Eq. 1.
4
  
The average energy was taken for equivalent hydrogen atoms such as 3 hydrogen atoms of a methyl 
group.  The zero-point vibrational energy at the absolute zero temperature was added to the 
average energy. 
 
E = E(radical of substrate) + E(H) - E(substrate) (1) 
 
6.2. Docking simulation 
A docking simulation was carried out for in silico prediction of the metabolite structures using 
FRED software in OEDocking
15
, version 3.0.1 (OpenEye Scientific Software, Inc.; Santa Fe, New 
Mexico, USA).  The multiconformer structure database of tebufenozide was generated by 
OMEGA, version 2.5.1 (OpenEye Scientific Software, Inc.; Santa Fe, New Mexico, USA) prior to 
docking.  The same structure of tebufenozide as that used for the hydrogen abstraction energy 
calculation was used as an initial structure for OMEGA.  Sixty conformers of tebufenozide were 
generated in the database.   




) of human CYP3A4 and the crystal 
structure (PDBID: 4GQS, chain A
9
) of human CYP2C19 were used for docking.  Receptor files 
were generated using the structures of CYP3A4 and CYP2C19 by MAKE_RECEPTOR, one of 
applications in OEDocking version 3.0.1 (OpenEye Scientific Software, Inc.; Santa Fe, New Mexico, 
USA), after an oxygen atom was attached to the heme-iron atom using Sybyl ver. 7.3.  The active 
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site boxes were defined for CYP3A4 and CYP2C19 by the default setting of MAKE RECEPTOR.  
The boxes included all heavy atoms of the heme.  The active site shape was described by a contour 
of the shape potential for each CYP enzyme and used for docking.  The shape potential was 
created by docking multiple drug-like molecular probes, which were stored internally by the 







 for CYP3A4: 3NXU, 3UA1, and CYP2C19, respectively. 
Each conformer in the multiconformer structure database of tebufenozide was attempted to dock 
into the active site shapes of CYP3A4 or CYP2C19 using FRED.  Scoring functions, Chemgauss3 
in the first exhaustive docking step and Chemgauss4 in the second optimization step were used for 
FRED to evaluate the ligand-receptor affinity.  The Chemgauss4 score is always a negative value.  
Thus, a pose with a larger absolute value of Chemgauss4 score was defined as the higher ranked 
pose.  The top 100 ranked poses in terms of the Chemgauss4 score for each CYP enzyme were 
selected.  A constraint condition was defined using a utility program, receptor_toolbox in 
OEDocking in order for every pose to have at least one heavy atom within 3.2 Å [The sum of van 
der Waals radii of carbon (1.7 Å) and oxygen (1.5 Å) atoms] of the oxygen atom attached to the 
heme-iron atom.  The top 100 ranked poses were filtered by the constraint condition.   
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Fig. 1.  Structure of tebufenozide 
Fig. 2.  Proposed MS fragmentation pathways for tebufenozide metabolites M1-M5 
Fig. 3.  Structures of tebufenozide metabolites with the production ratio by CYP3A4 and 
CYP2C19 
Fig. 4.  Examples of docking poses of tebufenozide to CYP3A4 (PDB ID: 3UA1) (A) and 
CYP2C19 (B).  Active site shapes and tebufenozide are shown by blue lines and the 
orange color, respectively.  The heme is located at the left side of each figure. 
Fig. 5. The synthesis scheme of compounds with the M1 structure (racemic compound and 
R-enantiomer) and M2 structure 
